Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
enzyme disorders
Biotech
GSK won't pick up Wave's genetic disease RNA editor
Wave plans to pursue accelerated approval for WVE-006, an experimental oligonucleotide for alpha-1 antitrypsin deficiency.
Darren Incorvaia
Feb 2, 2026 11:14am
Denali ph. 1 Pompe plans hit with clinical hold
Dec 4, 2025 11:52am
BioMarin inks $270M Inozyme buyout, bagging phase 3 prospect
May 16, 2025 8:46am
BioMarin's R&D head hopes pipeline of good ideas won't 'dry out'
Feb 21, 2025 7:00am
Syntis launches with obesity pill to mimic gastric bypass
Jun 11, 2024 7:00am
Takeda takes orphan drug to regulators after seeing phase 3 data
Jan 5, 2023 9:35am
